Frontiers in Immunology (Mar 2022)

Application of Regulatory Cell Death in Cancer: Based on Targeted Therapy and Immunotherapy

  • Xiaochen Qi,
  • Quanlin Li,
  • Xiangyu Che,
  • Qifei Wang,
  • Guangzhen Wu

DOI
https://doi.org/10.3389/fimmu.2022.837293
Journal volume & issue
Vol. 13

Abstract

Read online

The development of cancer treatment methods is constantly changing. For common cancers, our treatment methods are still based on conventional treatment methods, such as chemotherapy, radiotherapy, and targeted drug therapy. Nevertheless, the emergence of tumor resistance has a negative impact on treatment. Regulated cell death is a gene-regulated mode of programmed cell death. After receiving specific signal transduction, cells change their physical and chemical properties and the extracellular microenvironment, resulting in structural destruction and decomposition. As research accumulates, we now know that by precisely inducing specific cell death patterns, we can treat cancer with less collateral damage than other treatments. Many newly discovered types of RCD are thought to be useful for cancer treatment. However, some experimental results suggest that some RCDs are not sensitive to cancer cell death, and some may even promote cancer progression. This review summarizes the discovered types of RCDs, reviews their clinical efficacy in cancer treatment, explores their anticancer mechanisms, and discusses the feasibility of some newly discovered RCDs for cancer treatment in combination with the immune and tumor microenvironment.

Keywords